T-Cell Large Granular Lymphocyte Leukemia
Associated Genetic Biomarkers
NCI Definition: A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) 
T-cell large granular lymphocyte leukemias most frequently harbor alterations in STAT3, TET2, KMT2A, WT1, and TNFAIP3 .
STAT3 Mutation, STAT3 Exon 21 Mutation, TET2 Mutation, STAT3 Y640F, and TET2 Nonsense are the most common alterations in T-cell large granular lymphocyte leukemia .
There are 2 clinical trials for T-cell large granular lymphocyte leukemia, of which 1 is open and 1 is completed or closed. Of the trials that contain T-cell large granular lymphocyte leukemia as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open).
CD4 is the most frequent gene inclusion criterion for T-cell large granular lymphocyte leukemia clinical trials .
Bnz-1 and anti-cd4 chimeric antigen receptor t-cells are the most common interventions in T-cell large granular lymphocyte leukemia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.